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Objectives:  The  authors  present  the  section  of  the guidelines  of the  French  Otorhinolaryngology  Head
and  Neck  Surgery  Society  (SFORL)  for  the management  of  somatic  pain  induced  by  head  and  neck  cancer
treatment  concerning  management  of pain  following  radiation  therapy  and  chemotherapy.
Methods:  A  multidisciplinary  work  group  was  entrusted  with  a literature  review.  Guidelines  were  drawn
up based  on  the  articles  retrieved  and  the  group  members’  experience.  They  were  read  over  by an  editorial
group independent  of the work  group.  A coordination  meeting  drew  up the  ﬁnal  version.  Guidelines  were
graded  A,  B or C or  as expert  opinion  in decreasing  order  of  level  of  evidence.
Results:  Particular  care  should  be given  to detection  and  early  adapted  treatment  of pain  induced  by
radiation  therapy  and/or  chemotherapy,  to improve  quality  of life  in  head  and  neck  cancer  patients.
©  2014  Published  by Elsevier  Masson  SAS.. Introduction
Head and neck cancer is frequent in France, with 16,000 new
ases diagnosed yearly [1] (level of evidence 1). Management is
ounded on treatment by surgery, radiation therapy or chemother-
py.
These treatments may  be applied in isolation or association.
hey may  induce painful symptomatology. The present article deals
ith the management of somatic pain induced by radiation therapy
RT) and/or chemotherapy.
∗ Corresponding author.
E-mail address: d.blanchard@baclesse.fr (D. Blanchard).
http://dx.doi.org/10.1016/j.anorl.2014.07.001
879-7296/© 2014 Published by Elsevier Masson SAS.2. Method
A multidisciplinary work group was set up and entrusted
with a review of the literature. The group met several times
and drew up a position paper for the guidelines. The resulting
texts were read over by an editorial group independent of the
work group. A coordination meeting drew up the ﬁnal guide-
lines.
Guidelines were graded A, B or C by decreasing level of evi-
dence, following the literature analysis and guidelines grading
guide published by the ANAES national health accreditation and
assessment agency (January 2000, Table 1). This classiﬁcation is
intended to explain the bases upon which the guidelines are estab-
lished.
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Table  1
Levels of evidence and guideline grades.
Level of evidence from the literature Guideline grade
Level 1
High-power randomized comparative
studies
Meta-analysis of randomized comparative
studies
Decision analysis based on well-conducted
studies
Grade A
Established proof
Level 2
Low-power randomized comparative studies
Well-conducted non-randomized
comparative studies
Cohort studies
Grade B
Scientiﬁc presumption
Level 3
Case-control studies
Comparative studies with historical series
Grade C
Low level of evidence
Level 4
Comparative studies with serious bias
Retrospective studies
Case series
Descriptive epidemiological studies
(transverse, longitudinal)
Any other publication (case report, expert
opinion, etc.)
No publication
Professional agreement
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•able adapted from Sackett Score, following the ANAES guide to literature analysis and
rading of guidelines of January 2000.
. Guidelines
.1. Prevention and treatment of pain following radiation therapy
.1.1. General prevention
Immediate post-RT pain is closely related to inﬂammation of
he mucosa (mucositis) and skin (dermatitis) in the radiation ﬁeld.
ate pain is related to radiation-induced ﬁbrosis of support tissue:
ostoclavicular or temporomandibular joint disorder, trismus, neu-
opathic pain, or more rarely brachial plexitis with loss of motor
unction.
RT, of whatever type, can induce pain, with intensity correlat-
ng with total dose and potentiation by chemotherapy [2] (level of
vidence 1) or anti-EGFR antibodies and inversely correlating with
otal RT duration.
Prevention thus depends on treatment optimization in terms of
rradiated volume, total dose and dose per session and associated
otentiation.
As well as the obvious quality of life impact [3] (level of evidence
), pain may  necessitate interruption or termination of RT, impair-
ng the chances of cure. The probability of tumour control has been
hown to decrease by 1.4% per day of RT interruption [4] (level of
vidence 3).
In recent years, RT techniques have progressed with the advent
f conformal and intensity-modulated radiation, enabling better
daptation of dose to tumour and reduced exposure of healthy
rgans (conserved salivary function and reduced xerostomia [5]
level of evidence 2)).
These high-tech RT techniques improve quality of life [3,6] (level
f evidence 3).
Guideline 1
To limit early and late toxicity, RT should at least be con-
formal and, if indicated, intensity-modulated, to deliver a
homogeneous dose to target volumes and spare healthy tissue
as far as possible (Grade B).logy, Head and Neck diseases 131 (2014) 253–256
3.2. Prevention and treatment of acute post-RT complications
Management of acute pain (with onset during RT or generally
within 9 weeks) consists in the usual WHO  stepwise treatment of
background and episodic (including paroxysmal) pain.
3.2.1. Prevention and treatment of radiation-induced mucositis
Onset of mucositis is classically at the end of the ﬁrst week of
RT and healing is usually achieved within 2 to 3 weeks of end of
therapy [7,8] (level of evidence 4). Certain comorbidities, such as
denutrition, should be screened as risk factors for mucositis [9]
(level of evidence 4). Nutritional assessment should systematically
precede RT. Once established, radiation-induced mucositis induces
background pain exacerbated by paroxysmal episodes, mainly trig-
gered by feeding or mere swallowing. Odynophagia, if not properly
corrected, may  lead to nutritional deﬁciencies which in turn may
impair healing. Enteral feeding should be initiated early when there
is risk of severe dysphagia, especially in case of potentiation [9,10]
(level of evidence 3).
Smoking increases the intensity and duration of pain, due to
increased local inﬂammation.
Prevention of pain is thus based on precise patient informa-
tion (or “education”) regarding hygiene and diet and also postural
instructions, and preventing smoking and alcohol abuse (guide-
lines of the French Health Authority and National Cancer Institute:
HAS/INCa).
Guideline 2
To reduce RT-induced pain, patients should be prescribed
a nutritional assessment with hygiene and diet and postural
instructions and cessation of smoking and alcohol abuse
(Grade B).
Oral and dental care and hygiene should be systematic [8] (level
of evidence 2). It is recommended to:
• assess and eradicate dental infection sites ahead of RT and trans-
mit  irradiated volumes to the dentist;
• use a soft toothbrush, replacing it regularly [9] (level of evidence
3);
• apply ﬂuoride (Fluocaril Bi Fluore 2000®: the only ﬂuoride gel
with market authorization in France) to the thermoformed gut-
ters throughout RT and then lifelong;
• perform regular mouth-rinse with non-alcoholic saline solution
[9] (level of evidence 2).
Bacterial, fungal or viral superinfection should be screened
for, as it prolongs and exacerbates lesions, while treatment helps
relieve pain.
Guideline 3
To prevent and treat radiation-induced mucositis, it is rec-
ommended to (Grade B):
• assess and eradicate dental infection sites ahead of RT and
transmit irradiated volumes to the dentist;
• use a soft toothbrush, replacing it regularly;
• apply ﬂuoride to the dental splints;
• perform regular mouth-rinse with non-alcoholic saline solu-
tion;
ensure early diagnosis and treatment of any bacterial, fungal
or viral superinfection.
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Duloxetine has shown efﬁcacy in diabetic neuropathy. A ran-D. Blanchard et al. / European Annals of Otorhinola
The 2011 European Society for Medical Oncology (ESMO)
uidelines recommended benzydamine rinse (a local non-steroid
nti-inﬂammatory) [9] (level of evidence 2), whereas the Cochrane
011 meta-analysis reported minimal and unreliable beneﬁt (4
tudies, 332 patients [11]; level of evidence 2), and minimal and
nreliable beneﬁt with Aloe vera (minimal and unreliable beneﬁt
or the prevention of moderate or severe mucositis) or Sucralfate
[11] (level of evidence 2: intermediate), and not recommended by
SMO [9]). Chlorhexidine rinse is not recommended [9,11] (level of
vidence 2).
Local anesthetics may  provide transient pain relief (anecdotal
vidence) [9] (level of evidence 4).
A presently unpublished randomized double-blind study
eports that doxepin rinse (Quitaxon®) signiﬁcantly reduced pain
n radiation-induced mucositis [12] (level of evidence 2).
In case of standard fractionated RT, amifostine has market
uthorization for the prevention of acute and late xerostomia. It
rovides minimal and unreliable beneﬁt in preventing moderate
r severe mucositis [11] (level of evidence 2).
Treatment by low-frequency laser (wavelength 632.8 nm)  was
uggested, but not recommended, in 3 randomized studies, for the
revention of radiation-induced mucositis in non-potentiated head
nd neck RT [13] (level of evidence 2).
.2.2. Prevention and treatment of radiation-induced dermatitis
Recommended preventive measures [14,15] (level of evidence
) comprise: avoidance of irritating factors (sun exposure), washing
he skin with water with or without mild soap, loose cotton cloth-
ng (avoiding mechanical irritation) and avoiding alcohol-based
osmetics (chemical products such as perfumes).
For radiation-induced grade I and II epidermatitis without cuta-
eous invasion [14,16] (level of evidence 2), it may  be useful to
ydrate the skin after the RT session to improve comfort, while
hecking for absence of allergy [17] (level of evidence 3), and to
pply local corticosteroids in case of pruritus or silver sulfadiazine
Flamazine®), which can reduce radiation-induced epidermatitis.
In case of broken skin (grade II or III), hydrocolloid dressings are
ecommended [17] (level of evidence 2).
.3. Prevention and treatment of late post-RT complications
Late post-RT pain involves onset more than 6 months after ter-
ination of RT.
.3.1. Prevention and treatment of dental complications and
steoradionecrosis (ORN)
Most dental complications implicate qualitative and quantita-
ive changes in saliva. Demineralization is associated with impaired
alivary buffer action, and progresses to insidious decay with peri-
dontal disease and ORN [18] (level of evidence 3).
In oral or oropharyngeal RT, it is essential to protect the
andible with a lead mask.
Patient awareness (education) of oral and dental hygiene is pri-
ordial.
Oral and dental monitoring is indispensable, before, during and
fter RT (HAS/INCa guidelines, patient guide, September 2010).
Fluoride gel dental protection gutters should be applied daily
or life.
In dental or periodontal surgery, local anesthesia should not
nclude vasoconstrictors. Each procedure should be associated to
one-penetrating antibiotherapy. Gum suture is mandatory.In incipient ORN, medical treatment following Delanian’s “Pen-
oclo” protocol [19] (level of evidence 3) has been implemented for
ome years now, associated to the above-mentioned oral and dental
ygiene education. This speciﬁc treatment of ORN physiopathologylogy, Head and Neck diseases 131 (2014) 253–256 255
is associated to mild resection of bone sequesters, to limit radiation-
induced ﬁbrosis and reactivate osteoblastic healing.
In case of failure of medical treatment or of ORN fracture, radical
surgery is required, preferably associated to reconstruction.
3.3.2. Prevention and treatment of muscle pain
RT patients frequently present painful spasms and anterior cer-
vical contracture in what is known as radiation-induced cervical
dystonia [20] (level of evidence 4). This is related to histologic
changes in nerve ﬁbers by demyelinization in a context of evolv-
ing myofascial tissue ﬁbrosis at doses exceeding 60 Gy  [21] (level
of evidence 1).
To avoid such ﬁbrosis, contracture and painful posture and
facilitate lymphatic drainage (submental post-radiation oedema),
physiotherapy with massage and neck movement may  be useful
(HAS/INCa guidelines, patient guide, September 2010).
Rehabilitation should be early and prolonged to maintain cervi-
cal function. Antispasmodics and opioids combat spasms and pain.
Botulinum toxin type-A injection can relieve pain and reduce
spasm by its myorelaxant action in case of cervical dystonia or
trismus [22,23] (level of evidence 4).
Guideline 4
It is recommended to stress preventive measures against
painful late complications of RT (Expert opinion).
4. Prevention and treatment of post-chemotherapy pain
Chemotherapy-induced pain relates to onset of neuropathy or
mucositis.
4.1. Post-chemotherapy neuropathy
Post-chemotherapy neuropathy may  be irreversible and can be
secondary to chemotherapy based on platinum (cisplatin), vinca
alkaloids (vinorelbine) or taxanes (docetaxel, paclitaxel). The back-
ground health status typical of head and neck cancer patients
(alcohol abuse, diabetes, denutrition) is an aggravating factor.
Cisplatin causes late neuropathy, with onset sometimes remote
from treatment. The neuropathy is cumulative, mainly acting on
large ﬁbber sensory transmission. Toxicity in the spinal ganglion
of the sensory nerve has been reported, due to accumulation of
chemicals in the sensory nerve, the absence of any blood-nerve
barrier here increasing the accumulation of platinum.
Such complications are also found, dose-dependently, with tax-
anes, and especially paclitaxel: reversible distal, predominantly
sensory, sensory-motor polyneuropathy. It is rarely severe with
doses < 200 mg/m2 per cycle of paclitaxel. Docetaxel toxicity is
rarely dose-limiting.
Therapy is purely preventive: monitoring dose accumulation
and withdrawing the molecule implicated in neurologic disorder
persisting into the following cycle.
Treatment is symptomatic, with drugs acting on neuropathic
pain, at progressively increasing dose.
There have been numerous trials for various molecules as cura-
tive or preventive agents in post-chemotherapy neuropathy. Most
were negative, or with series too small to found recommendation.domized double-blind phase-III trial was  therefore performed: 231
patients received duloxetine 60 mg/day versus placebo for pacli-
taxel, oxaliplatin, docetaxel or cisplatin-induced neuropathy, and
experienced signiﬁcant relief [24] (level of evidence 2).
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Guideline 5
Early screening is recommended for chemotherapy-
induced neuropathy, to adapt dosage or modify or cease
treatment, given the lack of validated preventive or curative
treatment (Grade B).
.2. Chemotherapy-induced mucositis
Chemotherapy-induced mucositis presents as upper-airway
ucosa irritation of varying severity due to chemotherapy-induced
ytotoxicity.
Prevention and treatment are based on the same principles as
or radiation-induced mucositis.
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